CMS Entry id: 2709 | Channel: Blog landing page | Template: blog/index

Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

Blog

How can you measure behavior more accurately in your clinical trials?

Drug development typically relies upon clinical endpoints established within very controlled laboratory environments. Digital health technologies now provide the opportunity to transition data collection from the clinic into people’s personal lives, thereby providing more accurate conclusions about how a compound can influence their day-to-day life. 

Does using digital health in clinical trials generate real-world outcomes?

High-frequency digital health assessments can not only characterize clinically-relevant data as it occurs in real-time, but capture this information within the patient’s home environment. Therefore, digital health platforms provide an ecologically valid data source which directly maps on to an individual’s daily functioning and real-world outcomes. 

What is the optimal approach for using digital cognitive biomarkers in clinical trials?

Digital cognitive biomarkers are typically active or passive: but which approach enhances clinical trial success? Here we will define how active and passive cognitive biomarkers function in clinical trials, to conclude their optimal application.

What are digital cognitive biomarkers and why are they useful?

Biomarkers are important for the detection of disease-relevant information to help recruit, stratify and monitor patients, and to evaluate the safety and efficacy of compounds. Here we’ll discuss what digital biomarkers are and how they offer an opportunity to revolutionize research and drug development in psychiatric and neurological disorders. 

Using affective cognition to enhance precision psychiatry

Precision psychiatry is a promising new approach that seeks to improve outcomes in highly heterogeneous clinical populations.  

web-based testing, wearables, voice recognition, virtual clinical trials, transdiagnostic, technology, swm, subjective measures, stigma, social cognition, smartphones, set-shifting, screening, schizophrenia research, schizophrenia, rvp, risk-taking, research funding, research, remote testing, regulations, recruitment, prodromal, pro-cognitive, primary care, presenteeism, precision psychiatry, pre-clinical, personalised medicine, pen-and-paper, patient-centric, patient screening, patient recruitment, parkinson's disease, pal, ots, open access, occupational health, objective measures, novel, normative data, neurotech, neuroscience, near-patient testing, multiple sclerosis, ms, modelling, mental wellbeing, mental health at work, mental health, mci, major depression, longitudinal, inflammation, ied, high frequency, healthcare, guide, funding, ert, epidemiology, emotion recognition, ecoa, ebt, ebbinghaus, early career researchers, early alzheimer's disease, drug development, digital tools, digital health, depression, dementia, cognitive testing, cognitive science, cognitive safety, cognitive impairment, cognitive function, cognitive dysfunction, cognitive deficits, cognitive biomarkers, cognitive assessment, cognition kit, cognition, cns summit, clinical trials, clinical trial, cias, cgt, cantab research grant, cantab for clinical trials, cantab, brain health, biomarkers, awards, automatic speech recognition, attention, alzheimer's disease, altitude, affective cognition, absenteeism,